BioPharmSignal logoBioPharmSignal

Biotech News

CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy

CVRx (CVRX)CVRxCommercial

MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Humana has issued

Open original release

Related news

CVRXCVRx2026-05-04 20:30 EST

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

ADPTAdaptive Biotechnologies2026-05-29 11:30 EST

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

XTNTXtant Medical2026-05-06 12:00 EST

Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped

IARTIntegra LifeSciences2026-05-05 10:00 EST

Integra LifeSciences Announces Leadership Transition

STIMNeuronetics2026-04-29 20:30 EST

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CVRXCVRx2026-04-20 20:30 EST

CVRx Announces Nomination of Michael Dale for Election to the Board of Directors

OMOutset Medical2026-04-06 20:05 EST

Outset Medical Names Derick Elliott as Executive Vice President of Commercial

ICCMIceCure Medical2026-07-14 12:32 EST

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

RXSTRxSight2026-04-08 20:05 EST

RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026

ICCMIceCure Medical2026-05-05 12:30 EST

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

View all latest news

CVRx

CVRx is a medical device company focused on neuromodulation therapies for heart failure and hypertension-related conditions. Its products aim to address cardiovascular disease through implanted device technology.

Recent company news

CVRXCVRx2026-05-27 20:30 EST

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

CVRXCVRx2026-05-20 20:30 EST

CVRx to Present at the William Blair 46th Annual Growth Stock Conference

CVRXCVRx2026-05-14 12:00 EST

CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy

CVRXCVRx2026-05-11 20:05 EST

CVRx Reports First Quarter 2026 Financial and Operating Results

CVRXCVRx2026-05-04 20:30 EST

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

Stock data

Close
4.88 USD
Market cap
144.09M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States